MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:42Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Skin lightening agents]]
			[[Category:Depigmenting agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #274

2026-05-23T04:15:08Z

parser-claude batch MedTemplate pre-fill, Top 300 #274

New page

{{MedTemplate
| generic = Hydroquinone
| brand = Lustra, EpiQuin Micro, Melquin, Tri-Luma (with tretinoin and fluocinolone)
| structure =
| classes = [[:Category:Skin_lightening_agents|Skin-lightening agent]], [[:Category:Depigmenting_agents|Depigmenting agent]]
| uses = <vote slug="melasma-use">Melasma</vote>, <vote slug="post-inflammatory-hyperpigmentation-use">Post-inflammatory hyperpigmentation</vote>, <vote slug="ephelides-use">Ephelides/lentigines (selected)</vote>
| starting_dose = Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis
| preparations = 4% prescription cream/lotion; OTC 2% withdrawn in US (2020 CARES Act); compounded higher strengths available
| fda_max = 4% topical; limit duration of use
| pill_id =
| routes = Topical
| onset = Visible lightening at 4-12 weeks
| duration = Hours per application
| halflife = Not meaningfully described — topical local action with minimal systemic absorption<ref name="tri-luma-label">FDA Prescribing Information, Tri-Luma (fluocinolone, hydroquinone, tretinoin), Galderma, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021112s016lbl.pdf</ref>
| bioavailability = Topical with limited but measurable systemic absorption<ref name="tri-luma-label" />
| pregnancy = Generally avoided in pregnancy.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns)
| mechanism = <vote slug="hydroquinone-mech-claim">Hydroquinone inhibits tyrosinase, the rate-limiting enzyme converting tyrosine to melanin in melanocytes; reduced melanin synthesis lightens hyperpigmented skin over weeks.</vote> '''Exogenous ochronosis''' (paradoxical blue-black hyperpigmentation, irreversible) is the most-feared adverse effect of prolonged use and the basis for the typical 4-month course limit. Combination with tretinoin and a low-potency steroid (Kligman formula, marketed as Tri-Luma) is more effective than monotherapy for melasma<ref name="tri-luma-label" />.
}}

== References ==
<references />

Hydroquinone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #274